Navigation Links
Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
Date:5/7/2008

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Bank of America Healthcare Conference on Tuesday, May 13, 2008 at 10:00 a.m. PT in Las Vegas. Michael York, Senior Director of Investor Relations of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
2. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Amylin Pharmaceuticals to Webcast First Quarter Results
4. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
8. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
11. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique ... time adjusting, tweaking and testing virtual models and 3D ... judging. , “I enjoyed being involved as a judge,” ... entries showed a commendable range exploring the technical capabilities ... medium and the creativity of the contestants.” , Array ...
(Date:10/1/2014)... 30, 2014 New applications of structures ... have evolved in nature over millennia are featured in ... for applications in biophotonics in the October issue ... journal is published by SPIE, the international society for ... of the peer-reviewed articles are accessible via open access. ...
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... NicOx S.A.,(NYSE Euronext Paris: COX) today announced ... the commercial manufacture and supply of naproxcinod ... is NicOx, lead,investigational product and the first ... of,anti-inflammatory agents, which recently achieved positive results ...
... Sinovac Biotech Ltd. (NYSE Alternext,US: SVA), a leading provider of ... Fengtai District in the City of Beijing suspended,the use of ... of the death of a minor in the Fengtai District ... vaccine two days prior. , ...
... market research firm SharpBrains, will lead a webinar discussing the Top ... providers. , ... San Francisco, CA (PRWEB) December 2, ... World Economic Forum,s Council on the Challenges of Gerontology, will lead ...
Cached Biology Technology:NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Sinovac Releases Statement on Healive Vaccine Suspension 2Top 10 Cognitive Fitness Events of 2008 to be Unveiled at SharpBrains' Webinar 2Top 10 Cognitive Fitness Events of 2008 to be Unveiled at SharpBrains' Webinar 3
(Date:10/1/2014)... microbes that thrive in the deserts, rainforests, prairies and ... beneath New York City,s Central Park, according to a ... the University of Colorado Boulder. , The research ... Park,s 843 acres and discovered a stunning diversity of ... before. , Only 8.5 percent to 16.2 percent ...
(Date:9/30/2014)... by the Ocean Health Index rates the Earth,s ... health. In addition, for the first time, the ... regions beyond national jurisdiction (high-seas areas) all ... biodiversity and providing sustainable food sources. , In ... partnership led by scientists from UC Santa Barbara,s ...
(Date:9/30/2014)... scientists and engineers, led by Clemson University associate ... million grant from the U.S. Department of Energy,s ... a direct positive impact on South Carolina in ... radioactive contaminants. , "Understanding the scientific and engineering ... aspects of nuclear technologies is imperative if South ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3Rating the planet's oceans 2Rating the planet's oceans 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... (March 5, 2013) Researchers have discovered that deleting a ... on a high fat diet, a finding they believe may ... induces obesity these mice don,t get fat," said Prof. James ... research for Obstetrics and Gynecology at the University of Colorado ...
... Center scientists report the first successful blocking of tumor development in ... my knowledge, this is the first time that a mouse model ... which the formation of the tumor from beginning to end can ... of the tumor," said Dr. Luis Parada , chair of ...
... 2013) Researchers at the University of Minnesota,s ... cellular reprogramming to generate stem cells capable of ... Muscular Dystrophy (DMD). The research, which ... pluripotent stem cell technology and genetic correction to ...
Cached Biology News:Researchers discover gene that causes obesity in mice 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 3U of M researchers utilize genetically corrected stem cells to spark muscle regeneration 2U of M researchers utilize genetically corrected stem cells to spark muscle regeneration 3
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
... used in conjuction with Annexin V-FITC to ... stages of apoptosis (Annexin V positive, PI ... stages of apoptosis or already dead (Annexin ... in the orange range of the spectrum ...
... were cultured in RPMI 1640 with 2 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
Biology Products: